{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,10]],"date-time":"2026-01-10T22:30:45Z","timestamp":1768084245856,"version":"3.49.0"},"reference-count":66,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2021,5,24]],"date-time":"2021-05-24T00:00:00Z","timestamp":1621814400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,5,24]],"date-time":"2021-05-24T00:00:00Z","timestamp":1621814400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100004731","name":"Natural Science Foundation of Zhejiang Province","doi-asserted-by":"publisher","award":["LY18H310012"],"award-info":[{"award-number":["LY18H310012"]}],"id":[{"id":"10.13039\/501100004731","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Hangzhou City Scientific Technology Research Foundation of Zhejiang Province, China"},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81702801"],"award-info":[{"award-number":["81702801"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002858","name":"China Postdoctoral Science Foundation","doi-asserted-by":"publisher","award":["2020M680130"],"award-info":[{"award-number":["2020M680130"]}],"id":[{"id":"10.13039\/501100002858","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cell Death Dis"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Human intestinal peptide transporter PEPT1 is commonly repressed in human colorectal cancer (CRC), yet its relationship with sensitivity to the common CRC treatment ubenimex has not previously been elucidated. In this study, we confirmed PEPT1 suppression in CRC using real-time quantitative polymerase chain reaction and western blotting and then investigated the underlying epigenetic pathways involved using bisulfite sequencing, chromatin immunoprecipitation, siRNA knockdown, and reporter gene assays. We found that <jats:italic>PEPT1<\/jats:italic> transcriptional repression was due to both DNMT1-mediated DNA methylation of the proximal promoter region and HDAC1-mediated histone deacetylation, which blocked P300-mediated H3K18\/27Ac at the <jats:italic>PEPT1<\/jats:italic> distal promoter. Finally, the effects of the epigenetic activation of PEPT1 on the CRC response to ubenimex were evaluated using sequential combination therapy of decitabine and ubenimex both in vitro and in xenografts. In conclusion, epigenetic silencing of PEPT1 due to increased DNMT1 and HDAC1 expression plays a vital role in the poor response of CRC to ubenimex.<\/jats:p>","DOI":"10.1038\/s41419-021-03814-5","type":"journal-article","created":{"date-parts":[[2021,5,24]],"date-time":"2021-05-24T19:02:33Z","timestamp":1621882953000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["Epigenetic regulation of intestinal peptide transporter PEPT1 as a potential strategy for colorectal cancer sensitization"],"prefix":"10.1038","volume":"12","author":[{"given":"Yanhong","family":"Wang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiaqi","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lingrong","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Liqing","family":"Qiu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuhui","family":"Hua","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shixiu","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Su","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lushan","family":"Yu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaoli","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,5,24]]},"reference":[{"key":"3814_CR1","doi-asserted-by":"publisher","unstructured":"Sung, H. et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. Cancer J. Clin. caac.21660 https:\/\/doi.org\/10.3322\/caac.21660 (2021).","DOI":"10.3322\/caac.21660"},{"key":"3814_CR2","doi-asserted-by":"publisher","first-page":"1467","DOI":"10.1016\/S0140-6736(19)32319-0","volume":"394","author":"E Dekker","year":"2019","unstructured":"Dekker, E., Tanis, P. J., Vleugels, J. L. A., Kasi, P. M. & Wallace, M. B. Colorectal cancer. Lancet 394, 1467\u20131480 (2019).","journal-title":"Lancet"},{"key":"3814_CR3","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/j.drup.2016.05.001","volume":"27","author":"W Li","year":"2016","unstructured":"Li, W. et al. Overcoming ABC transporter-mediated multidrug resistance: molecular mechanisms and novel therapeutic drug strategies. Drug Resist. Updat. 27, 14\u201329 (2016).","journal-title":"Drug Resist. Updat."},{"key":"3814_CR4","doi-asserted-by":"publisher","first-page":"348ra97","DOI":"10.1126\/scitranslmed.aaf3124","volume":"8","author":"Y Liu","year":"2016","unstructured":"Liu, Y. et al. Epigenetic activation of the drug transporter OCT2 sensitizes renal cell carcinoma to oxaliplatin. Sci. Transl. Med. 8, 348ra97\u2013348ra97 (2016).","journal-title":"Sci. Transl. Med."},{"key":"3814_CR5","doi-asserted-by":"publisher","first-page":"4209","DOI":"10.1111\/bph.14467","volume":"175","author":"C Ye","year":"2018","unstructured":"Ye, C. et al. Inhibition of histone deacetylase 7 reverses concentrative nucleoside transporter 2 repression in colorectal cancer by up-regulating histone acetylation state: CNT2 repression in colorectal cancer. Br. J. Pharmacol. 175, 4209\u20134217 (2018).","journal-title":"Br. J. Pharmacol."},{"key":"3814_CR6","doi-asserted-by":"publisher","first-page":"610","DOI":"10.1007\/s00424-003-1101-4","volume":"447","author":"H Daniel","year":"2004","unstructured":"Daniel, H. & Kottra, G. The proton oligopeptide cotransporter family SLC15 in physiology and pharmacology. Pflug. Arch. 447, 610\u2013618 (2004).","journal-title":"Pflug. Arch."},{"key":"3814_CR7","doi-asserted-by":"publisher","first-page":"664","DOI":"10.1021\/mp100234z","volume":"8","author":"R Agu","year":"2011","unstructured":"Agu, R. et al. Proton-coupled oligopeptide transporter (POT) family expression in human nasal epithelium and their drug transport potential. Mol. Pharm. 8, 664\u2013672 (2011).","journal-title":"Mol. Pharm."},{"key":"3814_CR8","doi-asserted-by":"publisher","first-page":"1244","DOI":"10.1023\/A:1011996009332","volume":"15","author":"DE Smith","year":"1998","unstructured":"Smith, D. E. et al. Tubular localization and tissue distribution of peptide transporters in rat kidney. Pharm. Res. 15, 1244\u20131249 (1998).","journal-title":"Pharm. Res."},{"key":"3814_CR9","doi-asserted-by":"publisher","first-page":"1666","DOI":"10.1053\/gast.2001.24845","volume":"120","author":"D Merlin","year":"2001","unstructured":"Merlin, D. et al. Colonic epithelial hPepT1 expression occurs in inflammatory bowel disease: transport of bacterial peptides influences expression of MHC class 1 molecules. Gastroenterology 120, 1666\u20131679 (2001).","journal-title":"Gastroenterology"},{"key":"3814_CR10","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1002\/pros.22568","volume":"73","author":"D Sun","year":"2013","unstructured":"Sun, D. et al. Expression of proton-coupled oligopeptide transporter (POTs) in prostate of mice and patients with benign prostatic hyperplasia (BPH) and prostate cancer (PCa). Prostate 73, 287\u2013295 (2013).","journal-title":"Prostate"},{"key":"3814_CR11","doi-asserted-by":"publisher","first-page":"3511","DOI":"10.2147\/DDDT.S151725","volume":"11","author":"C-Y Wang","year":"2017","unstructured":"Wang, C.-Y., Liu, S., Xie, X.-N. & Tan, Z.-R. Regulation profile of the intestinal peptide transporter 1 (PepT1). Drug Des. Dev. Ther. 11, 3511\u20133517 (2017).","journal-title":"Drug Des. Dev. Ther."},{"key":"3814_CR12","doi-asserted-by":"publisher","first-page":"922","DOI":"10.1093\/ajcn\/75.5.922","volume":"75","author":"TR Ziegler","year":"2002","unstructured":"Ziegler, T. R. et al. Distribution of the H+\/peptide transporter PepT1 in human intestine: up-regulated expression in the colonic mucosa of patients with short-bowel syndrome. Am. J. Clin. Nutr. 75, 922\u2013930 (2002).","journal-title":"Am. J. Clin. Nutr."},{"key":"3814_CR13","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/0014-5793(96)00778-8","volume":"392","author":"Y Sai","year":"1996","unstructured":"Sai, Y. et al. Immunolocalization and pharmacological relevance of oligopeptide transporter PepT1 in intestinal absorption of beta-lactam antibiotics. FEBS Lett. 392, 25\u201329 (1996).","journal-title":"FEBS Lett."},{"key":"3814_CR14","doi-asserted-by":"publisher","first-page":"G66","DOI":"10.1152\/ajpgi.00491.2012","volume":"305","author":"T Wuensch","year":"2013","unstructured":"Wuensch, T. et al. The peptide transporter PEPT1 is expressed in distal colon in rodents and humans and contributes to water absorption. Am. J. Physiol. Gastrointest. Liver Physiol. 305, G66\u2013G73 (2013).","journal-title":"Am. J. Physiol. Gastrointest. Liver Physiol."},{"key":"3814_CR15","doi-asserted-by":"publisher","first-page":"804","DOI":"10.1073\/pnas.1813715116","volume":"116","author":"GS Minhas","year":"2019","unstructured":"Minhas, G. S. & Newstead, S. Structural basis for prodrug recognition by the SLC15 family of proton-coupled peptide transporters. Proc. Natl Acad. Sci. USA 116, 804\u2013809 (2019).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"3814_CR16","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/0753-3322(91)90123-B","volume":"45","author":"K Ota","year":"1991","unstructured":"Ota, K. Review of ubenimex (Bestatin): clinical research. Biomed. Pharmacother. 45, 55\u201360 (1991).","journal-title":"Biomed. Pharmacother."},{"key":"3814_CR17","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1038\/sj.leu.2401388","volume":"13","author":"K Sekine","year":"1999","unstructured":"Sekine, K., Fujii, H. & Abe, F. Induction of apoptosis by bestatin (ubenimex) in human leukemic cell lines. Leukemia 13, 729\u2013734 (1999).","journal-title":"Leukemia"},{"key":"3814_CR18","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1002\/1097-0215(20001015)88:2<274::AID-IJC20>3.0.CO;2-5","volume":"88","author":"T Nakanishi","year":"2000","unstructured":"Nakanishi, T., Tamai, I., Takaki, A. & Tsuji, A. Cancer cell-targeted drug delivery utilizing oligopeptide transport activity. Int. J. Cancer 88, 274\u2013280 (2000).","journal-title":"Int. J. Cancer"},{"key":"3814_CR19","doi-asserted-by":"publisher","first-page":"G471","DOI":"10.1152\/ajpgi.00025.2005","volume":"289","author":"J Shimakura","year":"2005","unstructured":"Shimakura, J., Terada, T., Katsura, T. & Inui, K.-I. Characterization of the human peptide transporter PEPT1 promoter: Sp1 functions as a basal transcriptional regulator of human PEPT1. Am. J. Physiol. Gastrointest. Liver Physiol. 289, G471\u2013G477 (2005).","journal-title":"Am. J. Physiol. Gastrointest. Liver Physiol."},{"key":"3814_CR20","doi-asserted-by":"publisher","first-page":"1581","DOI":"10.1016\/j.bcp.2006.03.001","volume":"71","author":"J Shimakura","year":"2006","unstructured":"Shimakura, J., Terada, T., Shimada, Y., Katsura, T. & Inui, K. The transcription factor Cdx2 regulates the intestine-specific expression of human peptide transporter 1 through functional interaction with Sp1. Biochem. Pharmacol. 71, 1581\u20131588 (2006).","journal-title":"Biochem. Pharmacol."},{"key":"3814_CR21","doi-asserted-by":"publisher","first-page":"1747","DOI":"10.1016\/j.bbagen.2013.12.026","volume":"1840","author":"KE Geillinger","year":"2014","unstructured":"Geillinger, K. E. et al. Nrf2 regulates the expression of the peptide transporter PEPT1 in the human colon carcinoma cell line Caco-2. Biochim. Biophys. Acta 1840, 1747\u20131754 (2014).","journal-title":"Biochim. Biophys. Acta"},{"key":"3814_CR22","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1038\/nature25477","volume":"554","author":"Z-M Zhang","year":"2018","unstructured":"Zhang, Z.-M. et al. Structural basis for DNMT3A-mediated de novo DNA methylation. Nature 554, 387\u2013391 (2018).","journal-title":"Nature"},{"key":"3814_CR23","doi-asserted-by":"publisher","first-page":"805","DOI":"10.1038\/nrg2651","volume":"10","author":"PA Jones","year":"2009","unstructured":"Jones, P. A. & Liang, G. Rethinking how DNA methylation patterns are maintained. Nat. Rev. Genet. 10, 805\u2013811 (2009).","journal-title":"Nat. Rev. Genet."},{"key":"3814_CR24","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1038\/nature08683","volume":"463","author":"GL Sen","year":"2010","unstructured":"Sen, G. L., Reuter, J. A., Webster, D. E., Zhu, L. & Khavari, P. A. DNMT1 maintains progenitor function in self-renewing somatic tissue. Nature 463, 563\u2013567 (2010).","journal-title":"Nature"},{"key":"3814_CR25","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1038\/ng1068","volume":"33","author":"M-F Robert","year":"2003","unstructured":"Robert, M.-F. et al. DNMT1 is required to maintain CpG methylation and aberrant gene silencing in human cancer cells. Nat. Genet. 33, 61\u201365 (2003).","journal-title":"Nat. Genet."},{"key":"3814_CR26","doi-asserted-by":"publisher","first-page":"21931","DOI":"10.1073\/pnas.1016071107","volume":"107","author":"MP Creyghton","year":"2010","unstructured":"Creyghton, M. P. et al. Histone H3K27ac separates active from poised enhancers and predicts developmental state. Proc. Natl Acad. Sci. USA 107, 21931\u201321936 (2010).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"3814_CR27","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1038\/emboj.2010.318","volume":"30","author":"Q Jin","year":"2011","unstructured":"Jin, Q. et al. Distinct roles of GCN5\/PCAF-mediated H3K9ac and CBP\/p300-mediated H3K18\/27ac in nuclear receptor transactivation. EMBO J. 30, 249\u2013262 (2011).","journal-title":"EMBO J."},{"key":"3814_CR28","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1038\/nrm3931","volume":"16","author":"E Verdin","year":"2015","unstructured":"Verdin, E. & Ott, M. 50 years of protein acetylation: from gene regulation to epigenetics, metabolism and beyond. Nat. Rev. Mol. Cell Biol. 16, 258\u2013264 (2015).","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"3814_CR29","doi-asserted-by":"publisher","DOI":"10.1186\/s13059-019-1870-5","volume":"20","author":"Z Zhao","year":"2019","unstructured":"Zhao, Z. & Shilatifard, A. Epigenetic modifications of histones in cancer. Genome Biol. 20, 245 (2019).","journal-title":"Genome Biol."},{"key":"3814_CR30","doi-asserted-by":"publisher","first-page":"1204","DOI":"10.1053\/j.gastro.2015.07.011","volume":"149","author":"Y Okugawa","year":"2015","unstructured":"Okugawa, Y., Grady, W. M. & Goel, A. Epigenetic alterations in colorectal cancer: emerging biomarkers. Gastroenterology 149, 1204\u20131225 (2015). e12.","journal-title":"Gastroenterology"},{"key":"3814_CR31","doi-asserted-by":"publisher","first-page":"744","DOI":"10.1053\/j.gastro.2019.05.057","volume":"157","author":"Y Luo","year":"2019","unstructured":"Luo, Y. et al. Intestinal PPAR\u03b1 protects against colon carcinogenesis via regulation of methyltransferases DNMT1 and PRMT6. Gastroenterology 157, 744\u2013759 (2019). e4.","journal-title":"Gastroenterology"},{"key":"3814_CR32","doi-asserted-by":"publisher","first-page":"1250","DOI":"10.1016\/j.molcel.2019.04.009","volume":"74","author":"Z Wang","year":"2019","unstructured":"Wang, Z. et al. Acetylation of PHF5A modulates stress responses and colorectal carcinogenesis through alternative splicing-mediated upregulation of KDM3A. Mol. Cell 74, 1250\u20131263 (2019).","journal-title":"Mol. Cell"},{"key":"3814_CR33","doi-asserted-by":"publisher","first-page":"1722","DOI":"10.1016\/j.celrep.2018.07.041","volume":"24","author":"R Raisner","year":"2018","unstructured":"Raisner, R. et al. Enhancer activity requires CBP\/P300 bromodomain-dependent histone H3K27 acetylation. Cell Rep. 24, 1722\u20131729 (2018).","journal-title":"Cell Rep."},{"key":"3814_CR34","doi-asserted-by":"publisher","first-page":"8344","DOI":"10.7150\/thno.30707","volume":"9","author":"J Peng","year":"2019","unstructured":"Peng, J. et al. p300\/CBP inhibitor A-485 alleviates acute liver injury by regulating macrophage activation and polarization. Theranostics 9, 8344\u20138361 (2019).","journal-title":"Theranostics"},{"key":"3814_CR35","doi-asserted-by":"publisher","first-page":"2826","DOI":"10.1128\/MCB.12.6.2826","volume":"12","author":"Y Rikitake","year":"1992","unstructured":"Rikitake, Y. & Moran, E. DNA-binding properties of the E1A-associated 300-kilodalton protein. Mol. Cell. Biol. 12, 2826\u20132836 (1992).","journal-title":"Mol. Cell. Biol."},{"key":"3814_CR36","doi-asserted-by":"publisher","first-page":"943","DOI":"10.2147\/OTT.S157480","volume":"11","author":"X Wang","year":"2018","unstructured":"Wang, X. et al. Role of ubenimex as an anticancer drug and its synergistic effect with Akt inhibitor in human A375 and A2058 cells. OncoTargets Ther. 11, 943\u2013953 (2018).","journal-title":"OncoTargets Ther."},{"key":"3814_CR37","doi-asserted-by":"publisher","first-page":"5787","DOI":"10.1016\/j.bmc.2016.09.033","volume":"24","author":"Y Jiang","year":"2016","unstructured":"Jiang, Y. et al. Discovery of a novel chimeric ubenimex-gemcitabine with potent oral antitumor activity. Bioorg. Med. Chem. 24, 5787\u20135795 (2016).","journal-title":"Bioorg. Med. Chem."},{"key":"3814_CR38","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.ejps.2014.06.019","volume":"63","author":"L Wang","year":"2014","unstructured":"Wang, L. et al. PEPT1- and OAT1\/3-mediated drug-drug interactions between bestatin and cefixime in vivo and in vitro in rats, and in vitro in human. Eur. J. Pharm. Sci. 63, 77\u201386 (2014).","journal-title":"Eur. J. Pharm. Sci."},{"key":"3814_CR39","doi-asserted-by":"publisher","first-page":"588","DOI":"10.1016\/j.ijpharm.2015.09.042","volume":"495","author":"Y Jia","year":"2015","unstructured":"Jia, Y. et al. Enhancement effect of resveratrol on the intestinal absorption of bestatin by regulating PEPT1, MDR1 and MRP2 in vivo and in vitro. Int. J. Pharm. 495, 588\u2013598 (2015).","journal-title":"Int. J. Pharm."},{"key":"3814_CR40","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1158\/0008-5472.CAN-09-1947","volume":"70","author":"T-C Chou","year":"2010","unstructured":"Chou, T.-C. Drug combination studies and their synergy quantification using the Chou-Talalay method. Cancer Res. 70, 440\u2013446 (2010).","journal-title":"Cancer Res."},{"key":"3814_CR41","doi-asserted-by":"crossref","unstructured":"Otsuki, T. et al. Aminopeptidase N\/CD13 as a potential therapeutic target in malignant pleural mesothelioma. Eur. Respir. J. 51, 1701610 (2018).","DOI":"10.1183\/13993003.01610-2017"},{"key":"3814_CR42","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2407-7-140","volume":"7","author":"M Terauchi","year":"2007","unstructured":"Terauchi, M. et al. Inhibition of APN\/CD13 leads to suppressed progressive potential in ovarian carcinoma cells. BMC Cancer 7, 140 (2007).","journal-title":"BMC Cancer"},{"key":"3814_CR43","doi-asserted-by":"publisher","first-page":"97","DOI":"10.7164\/antibiotics.29.97","volume":"29","author":"H Umezawa","year":"1976","unstructured":"Umezawa, H., Aoyagi, T., Suda, H., Hamada, M. & Takeuchi, T. Bestatin, an inhibitor of aminopeptidase B, produced by actinomycetes. J. Antibiot. 29, 97\u201399 (1976).","journal-title":"J. Antibiot."},{"key":"3814_CR44","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1016\/0006-2952(94)90232-1","volume":"48","author":"DT Muskardin","year":"1994","unstructured":"Muskardin, D. T., Voelkel, N. F. & Fitzpatrick, F. A. Modulation of pulmonary leukotriene formation and perfusion pressure by bestatin, an inhibitor of leukotriene A4 hydrolase. Biochem. Pharm. 48, 131\u2013137 (1994).","journal-title":"Biochem. Pharm."},{"key":"3814_CR45","doi-asserted-by":"publisher","first-page":"89","DOI":"10.3892\/ijo.2016.3496","volume":"49","author":"M Yamashita","year":"2016","unstructured":"Yamashita, M. et al. A CD13 inhibitor, ubenimex, synergistically enhances the effects of anticancer drugs in hepatocellular carcinoma. Int. J. Oncol. 49, 89\u201398 (2016).","journal-title":"Int. J. Oncol."},{"key":"3814_CR46","doi-asserted-by":"publisher","first-page":"114127","DOI":"10.1016\/j.bcp.2020.114127","volume":"180","author":"BR Thompson","year":"2020","unstructured":"Thompson, B. R., Shi, J., Zhu, H.-J. & Smith, D. E. Pharmacokinetics of gemcitabine and its amino acid ester prodrug following intravenous and oral administrations in mice. Biochem. Pharmacol. 180, 114127 (2020).","journal-title":"Biochem. Pharmacol."},{"key":"3814_CR47","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.sbi.2016.10.018","volume":"45","author":"S Newstead","year":"2017","unstructured":"Newstead, S. Recent advances in understanding proton coupled peptide transport via the POT family. Curr. Opin. Struct. Biol. 45, 17\u201324 (2017).","journal-title":"Curr. Opin. Struct. Biol."},{"key":"3814_CR48","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1093\/jac\/dkv340","volume":"71","author":"X Lu","year":"2016","unstructured":"Lu, X. et al. Human oligopeptide transporter 2 (PEPT2) mediates cellular uptake of polymyxins. J. Antimicrob. Chemother. 71, 403\u2013412 (2016).","journal-title":"J. Antimicrob. Chemother."},{"key":"3814_CR49","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1038\/nature07861","volume":"459","author":"C Das","year":"2009","unstructured":"Das, C., Lucia, M. S., Hansen, K. C. & Tyler, J. K. CBP\/p300-mediated acetylation of histone H3 on lysine 56. Nature 459, 113\u2013117 (2009).","journal-title":"Nature"},{"key":"3814_CR50","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-12861-8","volume":"10","author":"S Manickavinayaham","year":"2019","unstructured":"Manickavinayaham, S. et al. E2F1 acetylation directs p300\/CBP-mediated histone acetylation at DNA double-strand breaks to facilitate repair. Nat. Commun. 10, 4951 (2019).","journal-title":"Nat. Commun."},{"key":"3814_CR51","doi-asserted-by":"publisher","first-page":"eaaw8500","DOI":"10.1126\/sciadv.aaw8500","volume":"6","author":"H-M Li","year":"2020","unstructured":"Li, H.-M. et al. A potent CBP\/p300-Snail interaction inhibitor suppresses tumor growth and metastasis in wild-type p53-expressing cancer. Sci. Adv. 6, eaaw8500 (2020).","journal-title":"Sci. Adv."},{"key":"3814_CR52","doi-asserted-by":"publisher","first-page":"5746","DOI":"10.1021\/bi400684q","volume":"52","author":"RA Henry","year":"2013","unstructured":"Henry, R. A., Kuo, Y.-M. & Andrews, A. J. Differences in specificity and selectivity between CBP and p300 acetylation of histone H3 and H3\/H4. Biochemistry 52, 5746\u20135759 (2013).","journal-title":"Biochemistry"},{"key":"3814_CR53","doi-asserted-by":"publisher","first-page":"2174","DOI":"10.1002\/eji.201343308","volume":"43","author":"B Gao","year":"2013","unstructured":"Gao, B. et al. p300, but not PCAF, collaborates with IRF-1 in stimulating TRIM22 expression independently of its histone acetyltransferase activity. Eur. J. Immunol. 43, 2174\u20132184 (2013).","journal-title":"Eur. J. Immunol."},{"key":"3814_CR54","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1186\/s12860-020-00296-9","volume":"21","author":"S Martire","year":"2020","unstructured":"Martire, S., Nguyen, J., Sundaresan, A. & Banaszynski, L. A. Differential contribution of p300 and CBP to regulatory element acetylation in mESCs. BMC Mol. Cell Biol. 21, 55 (2020).","journal-title":"BMC Mol. Cell Biol."},{"key":"3814_CR55","doi-asserted-by":"publisher","first-page":"1370","DOI":"10.1101\/gad.300624.117","volume":"31","author":"C Song","year":"2017","unstructured":"Song, C., Hotz-Wagenblatt, A., Voit, R. & Grummt, I. SIRT7 and the DEAD-box helicase DDX21 cooperate to resolve genomic R loops and safeguard genome stability. Genes Dev. 31, 1370\u20131381 (2017).","journal-title":"Genes Dev."},{"key":"3814_CR56","doi-asserted-by":"publisher","first-page":"13012","DOI":"10.1073\/pnas.1918845117","volume":"117","author":"J Xie","year":"2020","unstructured":"Xie, J. et al. Metformin selectively inhibits metastatic colorectal cancer with the KRAS mutation by intracellular accumulation through silencing MATE1. Proc. Natl Acad. Sci. USA 117, 13012\u201313022 (2020).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"3814_CR57","doi-asserted-by":"publisher","first-page":"1287","DOI":"10.1056\/NEJMoa1311194","volume":"370","author":"TF Imperiale","year":"2014","unstructured":"Imperiale, T. F. et al. Multitarget stool DNA testing for colorectal-cancer screening. N. Engl. J. Med. 370, 1287\u20131297 (2014).","journal-title":"N. Engl. J. Med."},{"key":"3814_CR58","first-page":"664","volume":"6","author":"L Lutz","year":"2016","unstructured":"Lutz, L. et al. Histone modifiers and marks define heterogeneous groups of colorectal carcinomas and affect responses to HDAC inhibitors in vitro. Am. J. Cancer Res. 6, 664\u2013676 (2016).","journal-title":"Am. J. Cancer Res."},{"key":"3814_CR59","doi-asserted-by":"publisher","first-page":"144851","DOI":"10.1016\/j.gene.2020.144851","volume":"754","author":"C Chen","year":"2020","unstructured":"Chen, C. et al. The histone deacetylase HDAC1 activates HIF1\u03b1\/VEGFA signal pathway in colorectal cancer. Gene 754, 144851 (2020).","journal-title":"Gene"},{"key":"3814_CR60","doi-asserted-by":"publisher","unstructured":"Kim, S. L., La, M. T., Shin, M. W., Kim, S.-W. & Kim, H.-K. A novel HDAC1 inhibitor, CBUD-1001, exerts anticancer effects by modulating the apoptosis and EMT of colorectal cancer cells. Int. J. Oncol. https:\/\/doi.org\/10.3892\/ijo.2020.5109 (2020).","DOI":"10.3892\/ijo.2020.5109"},{"key":"3814_CR61","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1038\/71750","volume":"24","author":"F Fuks","year":"2000","unstructured":"Fuks, F., Burgers, W. A., Brehm, A., Hughes-Davies, L. & Kouzarides, T. DNA methyltransferase Dnmt1 associates with histone deacetylase activity. Nat. Genet. 24, 88\u201391 (2000).","journal-title":"Nat. Genet."},{"key":"3814_CR62","doi-asserted-by":"publisher","first-page":"1427","DOI":"10.1093\/bioinformatics\/18.11.1427","volume":"18","author":"L-C Li","year":"2002","unstructured":"Li, L.-C. & Dahiya, R. MethPrimer: designing primers for methylation PCRs. Bioinformatics 18, 1427\u20131431 (2002).","journal-title":"Bioinformatics"},{"key":"3814_CR63","unstructured":"Eads, C. A. & Laird, P. W. Combined Bisulfite Restriction Analysis (COBRA). In DNA Methylation Protocols (eds. Mills, K. I. & Ramsahoye, B. H.) 71\u201386 (Springer, New York, 2002)."},{"key":"3814_CR64","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1038\/nprot.2006.98","volume":"1","author":"TI Lee","year":"2006","unstructured":"Lee, T. I., Johnstone, S. E. & Young, R. A. Chromatin immunoprecipitation and microarray-based analysis of protein location. Nat. Protoc. 1, 729\u2013748 (2006).","journal-title":"Nat. Protoc."},{"key":"3814_CR65","doi-asserted-by":"publisher","DOI":"10.1186\/1746-4811-3-11","volume":"3","author":"M Haring","year":"2007","unstructured":"Haring, M. et al. Chromatin immunoprecipitation: optimization, quantitative analysis and data normalization. Plant Methods 3, 11 (2007).","journal-title":"Plant Methods"},{"key":"3814_CR66","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1016\/j.ebiom.2019.05.008","volume":"44","author":"S Zhao","year":"2019","unstructured":"Zhao, S. et al. Inhibition of LTA4H by bestatin in human and mouse colorectal cancer. EBioMedicine 44, 361\u2013374 (2019).","journal-title":"EBioMedicine"}],"container-title":["Cell Death &amp; Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41419-021-03814-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41419-021-03814-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41419-021-03814-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,2]],"date-time":"2022-12-02T09:09:30Z","timestamp":1669972170000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41419-021-03814-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5,24]]},"references-count":66,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2021,6]]}},"alternative-id":["3814"],"URL":"https:\/\/doi.org\/10.1038\/s41419-021-03814-5","relation":{},"ISSN":["2041-4889"],"issn-type":[{"value":"2041-4889","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,5,24]]},"assertion":[{"value":"21 December 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 May 2021","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 May 2021","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 May 2021","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This project was approved by the Institutional Review Board of Hangzhou Cancer Hospital (Permit Number: HZCH-2017-09). All animal experiments were approved by the Zhejiang University Animal Care and Use Committee (Ethics Code: ZJU20200062).","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics statement"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"532"}}